Evaluation study on dementia Berlin-Brandenburg (VDBB)Epidemiological investigation on the impact of diagnosis, based on biomarker criteria, onto the treatment strategy on patients with cognitive impairment, in the sense of knowledge generating medicine.

• Conditions: F06.7; F00; Mild cognitive disorder; Dementia in Alzheimer disease

• Registration Number: DRKS00011375
• Lead Sponsor: DTZ Berlin

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-05-30
• Study Completion: 2021-02-11
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 41

Inclusion Criteria

1. Adults age = 75
2.Patients with mild cognitive impairment (MCI) or mild dementia (MMST = 20 points or DemTect = 9 points) with suspicion of Alzheimer's (Hachinski test < 4 points)
3.According to guidelines with biomarkers continuative diagnostics is recommended by the examining physician.
4.The patient is voluntarily taking part in the study and has given his written permission for the use of his pseudonymized patient data.

Exclusion Criteria

1. Previous amyloid PET scan with available investigating results.
2. Simultaneous participating in a clinical trial on disease-modifying treatments for Alzheimer's
3.Severe depression (GDS > 10 points)
4.The occurrence of a neurological disorder, frequently associated with dementia, e.g. Parkinson's disease
5.Significant discrepancies in the results of physical examination, vital functions and laboratory examination, which require further examination or treatment
6.Dependency disorders (e.g. benzodiazepine, alcohol)
7.Intake of cognitive impairing medication
8.Serious illness, that could prevent a participation throughout the entire observation period
9. Lives at a nursing home.
10. Pregnancy

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percentage of patients, whose diagnosis based on biomarker criteria differs from those, based on clinical diagnosis.

Secondary Outcome Measures

Name	Time	Method
a. Percentage of patients, whose theraply plan changed based on the biomarker criteria diagnosis<br>b. Modification of cognitive impairments within the patient group <br>c. Modification of the patient's quality of life<br>d. Modification of psychological and behavioural symptoms<br>e. Modification of resource utilization/costs